Analysis from the “Riaz 2017” cohort showed that low ACAP1 levels were associated with worse response and OS in melanoma patients treated with anti-PD-1 antibodies regardless of whether the samples were collected prior to or during therapy (Figure 9D). The gene discussed is ACAP1; the disease is melanoma.